Pelthos Therapeutics (PTHS) flags Q1 2026 misvaluation, restates debt and finds control weakness
Rhea-AI Filing Summary
Pelthos Therapeutics Inc. determined that its condensed consolidated financial statements for the quarter ended March 31, 2026 can no longer be relied upon due to a misapplication of ASC 820 in valuing Level 3 fair value measurements of its convertible debt. After reassessing the valuation methods and inputs during the June 30, 2026 fair value measurement, the company concluded a restatement of that interim period is required.
The restatement will increase the fair value of convertible debt liabilities by $15.8 million, reduce accumulated other comprehensive income by $1.0 million, and increase accumulated deficit by $14.8 million. It will also add $14.8 million of non-cash expense to other expense and reduce other comprehensive loss by $1.0 million related to instrument credit risk. These changes affect net loss and loss per share but do not affect liquidity, cash, revenues, operating expenses, or operating loss.
The company identified a material weakness in internal control over financial reporting as of March 31, 2026, relating to controls over Level 3 fair value measurements of convertible debt and the Convertible Notes Subordination Agreement provisions. Disclosure controls and procedures were not effective, and Pelthos plans to outline remediation steps in an amended Q1 2026 report and its Q2 2026 report.
Positive
- Restatement impact is non-cash and the company states there is no impact on liquidity or cash position for the affected period.
- Revenues, operating expenses and operating loss for the affected quarter remain unchanged, as the adjustments relate to other income (expense) only.
Negative
- Previously issued Q1 2026 financial statements are deemed not reliable and will be restated, undermining reporting credibility.
- Restatement increases the fair value of convertible debt liabilities by $15.8 million, weakening the reported balance sheet.
- Accumulated deficit will increase by $14.8 million due to additional non-cash expense, worsening historical equity.
- The company identified a material weakness in internal control over financial reporting as of March 31, 2026.
- Disclosure controls and procedures were not effective as of March 31, 2026, specifically around Level 3 fair value measurements for convertible debt.
8-K Event Classification
Item 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report
1 item
Item 4.02
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report
Governance
Previously issued financial statements should no longer be relied upon due to errors or restatements.
Key Figures
Increase in fair value of convertible debt: $15.8 million
Reduction in accumulated other comprehensive income: $1.0 million
Increase in accumulated deficit: $14.8 million
+2 more
5 metrics
Increase in fair value of convertible debt
$15.8 million
Increase in total liabilities in the restated March 31, 2026 balance sheet
Reduction in accumulated other comprehensive income
$1.0 million
Equity impact in the restated March 31, 2026 balance sheet
Increase in accumulated deficit
$14.8 million
Equity impact from additional non-cash expense for the affected period
Increase in non-cash expense
$14.8 million
Change in fair value of convertible debt in other (expense) income for Q1 2026
Decrease in change in fair value due to instrument credit risk
$1.0 million
Adjustment in other comprehensive loss for the affected period
Key Terms
ASC 820, Level 3 fair value measurements, convertible debt, material weakness, +2 more
6 terms
ASC 820 financial
"because of a misapplication of Accounting Standards Codification (“ASC”) 820, Fair Value Measurements"
ASC 820 is an accounting standard that tells companies how to measure and report the fair value of assets and liabilities when a clear market price doesn’t exist. It matters to investors because those reported fair values affect a company’s balance sheet and earnings, and the standard requires disclosure about how values were estimated—similar to knowing whether a used car’s listed price came from a recent sale or from an opinion, which helps assess reliability.
Level 3 fair value measurements financial
"related to certain Level 3 fair value measurements of the Company’s convertible debt"
convertible debt financial
"Level 3 fair value measurements of the Company’s convertible debt"
A convertible debt is a loan a company takes that gives the lender the option to swap the owed money for a set number of the company’s shares instead of getting cash back. It matters to investors because it can change who owns the company and how much their shares are worth: if lenders convert, existing shareholders can be diluted, but conversion can also signal confidence and reduce a company’s cash pressure — like getting a coupon that can be redeemed for store ownership rather than a refund.
material weakness financial
"resulted from a material weakness in its internal control over financial reporting"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
disclosure controls and procedures financial
"As of March 31, 2026, the Company's disclosure controls and procedures were not effective"
Policies, routines and internal checks a public company uses to identify, collect and verify information that must appear in its financial reports and public filings, and to make sure that material news is disclosed accurately and on time. Investors care because effective controls increase confidence that the company’s reported numbers and disclosures are reliable and reduce the risk of surprises, much like a building’s inspection and alarm system helps occupants trust the structure’s safety.
Convertible Notes Subordination Agreement financial
"provisions in the Convertible Notes Subordination Agreement entered into in January 2026"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Why is Pelthos Therapeutics (PTHS) restating its Q1 2026 financial statements?
Pelthos Therapeutics is restating Q1 2026 results due to a misapplication of ASC 820 in valuing Level 3 fair value measurements of its convertible debt. Certain subordination and conversion features were not properly reflected, making the prior statements unreliable.
How does the Pelthos Therapeutics (PTHS) restatement affect its liabilities and equity?
The restatement will increase the fair value of convertible debt liabilities by $15.8 million, reduce accumulated other comprehensive income by $1.0 million, and increase accumulated deficit by $14.8 million, negatively affecting reported equity.
Will the Pelthos Therapeutics (PTHS) restatement impact cash, liquidity, or operations?
The company states the restatement has no impact on liquidity or cash position. Revenues, operating expenses, and operating loss for the affected quarter are unchanged since the adjustments occur within other income (expense).
What internal control issues did Pelthos Therapeutics (PTHS) identify?
Pelthos identified a material weakness in internal control over financial reporting as of March 31, 2026, involving controls over valuation and review of Level 3 fair value measurements for convertible debt and a Convertible Notes Subordination Agreement.
Which financial statement line items at Pelthos Therapeutics (PTHS) will change due to the restatement?
The restatement affects the condensed consolidated balance sheet and statement of operations and comprehensive loss, including convertible debt fair value, accumulated other comprehensive income, accumulated deficit, non-cash expense, net loss, and net loss per share.
How is Pelthos Therapeutics (PTHS) addressing the identified material weakness?
Pelthos plans to describe remediation steps for the material weakness in its amended Q1 2026 report and Q2 2026 Form 10-Q, focusing on improving controls over Level 3 fair value measurements of its convertible debt.